Bronchitol Gets Final NICE OK, TOBI Podhaler Trumps Colobreathe
This article was originally published in The Pink Sheet Daily
Executive Summary
Pharmaxis’ Bronchitol became the first cystic fibrosis drug to get a NICE final approval, while Novartis’s TOBI Podhaler was selected ahead of Forest Lab’s Colobreathe for bacterial infection.
You may also be interested in...
European HTA: Cancer Drugs Suffer At NICE, Whilst IQWiG And HAS Also Tighten Purse Strings
Economic austerity and the resulting pressure on health care spend leaves little room for maneuver among Europe’s health technology assessment agencies.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.